Randomized Placebo-Controlled Trial for analyzing Efficacy of Homoeopathic Potentized Medicine Selenium in Autoimmune Hashimotos Thyroiditis
Phase 3
Completed
- Conditions
- Health Condition 1: E063- Autoimmune thyroiditis
- Registration Number
- CTRI/2021/02/030886
- Lead Sponsor
- Dr Elizabeth Abraham
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with either ATPO above 35 IU/ml or Anti Tg above 20 IU/ml
Exclusion Criteria
Cases with marked TSH level variations, multi-nodular goiters and malignant thyroid
tumors.
Patients with other severe systemic illness like uncontrolled diabetes, malignant
hypertension, other malignancies etc.
Immuno-compromised patients (AIDS, Cancer, TB)
Pregnant women and lactating mothers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Outcome of the treatment will be measured by assessing symptomatic <br/ ><br>improvement and considering reduction in antibody levels and also reduction in Wayne�s index and Billewicz score after trial in patients.Timepoint: 1 year follow up
- Secondary Outcome Measures
Name Time Method 1. To analyze efficacy of Homoeopathic potentized medicine Selenium in presenting co-morbidity related to autoimmune thyroiditis. <br/ ><br>2. To analyze which potency of Homoeopathic medicine Selenium is more effective in autoimmune thyroiditis.Timepoint: 1 year follow up